TLR4 mediates post-traumatic depression via kynurenine pathway activation in a murine traumatic brain injury model
Frontiers in Pharmacology · 15.04.2026 · 17
DOI: 10.3389/fphar.2026.1744031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 15.04.2026. Verfasst von Chang-Hong Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy, Anhui Medical University, Hefei, Anhui, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Depression
Abstract (Originalsprache)
Introduction
Traumatic brain injury (TBI) is a major risk factor for major depressive disorder (MDD), yet the underlying mechanisms remain poorly defined. This study demonstrates that toll-like receptor 4 (TLR4) activation drives depressive-like behaviors through dysregulation of the kynurenine pathway (KP) in a murine model of moderate TBI. Methods and Results Using male C57BL/6J mice subjected to controlled cortical impact, we observed depression-like phenotypes (reduced sucrose preference, prolonged immobility in forced swimming tests) specifically at 28 days post-TBI, with an incidence of 28.13%. Proteomics and immunofluorescence analyses revealed significant upregulation of hippocampal TLR4 expression and signaling pathway activation, concomitant with microglial activation. Crucially, the TLR4-specific inhibitor TAK-242 (administered i.p. from days 21–28 post-TBI) ameliorated depressive behaviors and suppressed phosphorylation of NF-κB p65. Mechanistically, TBI induced microglia-dependent upregulation of key KP enzymes indoleamine 2,3-dioxygenase 1 (IDO1) and kynurenine monooxygenase (KMO), leading to accumulation of the neurotoxic metabolite quinolinic acid (QUIN). This TLR4-KP axis was validated in vitro : LPS-stimulated BV2 microglia showed increased IDO1/KMO/QUIN expression, which was abolished by TAK-242 pretreatment.
Conclusion
Our findings establish a novel TLR4–KP–QUIN pathway as a critical mediator of post-TBI depression, providing a mechanistic basis for TLR4-targeted therapies. In addition to neuroinflammatory effects, this work mainly mediates dysregulation of TBI-related neuropsychiatric sequelae through metabolism, highlighting TLR4 inhibition as a promising strategy for mitigating chronic depressive outcomes after brain injury.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Anatomy, Anhui Medical University, Hefei, Anhui, China.
- The Molecular Biology Center, State Key Laboratory of Trauma and Chemical Poisoning, Department of Army Occupational Disease, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing, Chin…
- Center of Bone Metabolism and repair, Laboratory for Prevention and Rehabilitation of Training injuries, State Key Laboratory of Trauma and Chemical Poisoning, Trauma center, Research Institute of Surgery, Daping Hospit…
- Laboratory of Stem Cell and Tissue Engineering, Chongqing Medical University, Chongqing, China.
Zitieren
APA
Li, C. H., Wang, B., Gao, R. B., Peng, Y., Chen, K., Li, X. H., & Li, P. (2026). TLR4 mediates post-traumatic depression via kynurenine pathway activation in a murine traumatic brain injury model. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1744031
Vancouver
Li CH, Wang B, Gao RB, Peng Y, Chen K, Li XH, et al. TLR4 mediates post-traumatic depression via kynurenine pathway activation in a murine traumatic brain injury model. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1744031
BibTeX
@article{Li2026,
author = {Li, Chang-Hong and Wang, Bo and Gao, Ruo-Bing and Peng, Yan and Chen, Ke and Li, Xiao-Hui and Li, Ping},
title = {TLR4 mediates post-traumatic depression via kynurenine pathway activation in a murine traumatic brain injury model},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1744031}
}
EUVIMED